Memo - Magazine of European Medical Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Management of oligometastatic prostate cancer
ConclusionThe increased detection of omPCa due to advanced imaging necessitates an evolving treatment paradigm, encompassing systemic therapies, local treatments, and MDT. Current treatments largely rely on clinical disease burden and timing. We anticipate that diagnostic advancements and ongoing research will pave the way for personalized treatment options in omPCa management. (Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 18, 2023 Category: Cancer & Oncology Source Type: research

Diagnosis and management of mediastinal extragonadal germ cell tumors
SummaryExtragonadal germ cell tumors (EGCT) are rare and comprise only 2 –3% of all testicular germ cell tumors. The majority of EGCT are located in the mediastinum, followed by the retroperitoneum. Although histologically similar to germ cell tumors (GCT), EGCT have distinct histological patterns which result in a biologically aggressive variant of GCT with the need for interdisciplinary care in highly specialized centers. The majority of mediastinal EGCT harbor teratoma or yolk sac tumor elements. Treatment usually consists of a combination of systemic cytotoxic therapy and aggressive postchemotherapeutic surgery. Fi...
Source: Memo - Magazine of European Medical Oncology - December 18, 2023 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON CHRONIC LYMPHOCYTIC LEUKEMIA. Report from International Workshop on Chronic Lymphocytic Leukemia (XX iwCLL 2023), 6th –9th October, 2023, Boston, USA
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 12, 2023 Category: Cancer & Oncology Source Type: research

A GLOBAL CONGRESS DIGEST ON LUNG CANCER. Report from the ESMO Hybrid Congress , 20th – 24th October 2023, Madrid, Spain
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 12, 2023 Category: Cancer & Oncology Source Type: research

Emerging treatment strategies in chronic B-cell malignancies —News from ICML 2023
SummaryImplementation of targeted drugs in the treatment landscape of indolent B ‑cell malignancies has facilitated long-term remissions and reduced treatment-related toxicities for a substantial proportion of patients across several disease entities. Yet, adverse prognostic genetic aberrations such as TP53 dysfunctions and short-lived remissions after front-line therapy cann ot be fully compensated with currently licensed novel agents thereby predisposing affected patients to inferior clinical outcomes in the long run. Moreover, acquired resistance and increasing drug intolerability typically evolving with continuous t...
Source: Memo - Magazine of European Medical Oncology - December 5, 2023 Category: Cancer & Oncology Source Type: research

ASCO 2023: highlights in breast cancer
SummaryThe 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicago. While not immediately practice changing, results from several interesting studies in the field of breast cancer (BC) were reported. In the phase III NATALEE trial, the addition of 3 years of ribociclib to standard adjuvant endocrine therapy resulted in a significant improvement in invasive disease-free survival (iDFS), making this the second positive study of CDK4/6 inhibitors in the adjuvant setting. A subgroup analysis from the MONARCHe trial indicated sustained benefit of adjuvant abemaciclib ...
Source: Memo - Magazine of European Medical Oncology - December 5, 2023 Category: Cancer & Oncology Source Type: research

Cancer of unknown primary —state of the art
SummaryThe Cancer of Unknown Primary (CUP) syndrome does not represent a single clinical entity but comprises a diverse group of malignant tumors. CUP is defined as a histologically confirmed metastatic malignant disease for which the primary tumor cannot be identified after completing initial diagnostics. Although its incidence has decreased, managing CUP patients remains a significant clinical challenge, particularly for those in the poor prognosis group, where the overall survival is merely 3 months. In this context, accurate diagnostics and prompt treatment initiation are crucial. While platinum-based chemotherapy stil...
Source: Memo - Magazine of European Medical Oncology - December 5, 2023 Category: Cancer & Oncology Source Type: research

Prostate cancer special —part 1
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2023 Category: Cancer & Oncology Source Type: research

HER2 in focus —gastric cancer
(Source: Memo - Magazine of European Medical Oncology)
Source: Memo - Magazine of European Medical Oncology - December 1, 2023 Category: Cancer & Oncology Source Type: research